filmov
tv
Charles Fuchs, MD: Bevacizumab Side Effects
Показать описание
0:02:06
Charles Fuchs, MD: Bevacizumab Side Effects
0:01:48
Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
0:01:22
Charles Fuchs, MD: Bevacizumab Plus Chemotherapy
0:03:06
Charles Fuchs, MD: Chemotherapy Side Effects
0:01:26
Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
0:00:46
Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer
0:01:34
Charles Fuchs, MD: Impeding RAS Mutation Testing
0:01:57
Charles Fuchs, MD: Mutations in Colorectal Cancer
0:01:27
Charles Fuchs, MD: Treatment Toxicities and Quality of Life
0:01:59
Ovarian Cancer Subtypes May Predict Response to Bevacizumab
0:18:04
Why has everything beyond bevacizumab failed in angiogenesis inhibition?
0:04:03
Upfront Bevacizumab in Advanced Ovarian Cancer
0:04:12
Assessing the Use of Bevacizumab
0:01:15
Safety Findings of Long-Term Bevacizumab for Patients with Ovarian Cancer
0:08:15
Bevacizumab in Ovarian Cancer
0:01:19
Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer
0:01:40
Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer
0:05:41
Bevacizumab’s Role in Recurrent Ovarian Cancer
0:03:13
Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer
0:06:59
Optimizing Frontline Chemotherapy in Metastatic Colorectal Cancer
0:06:04
When to Add Bevacizumab for Recurrent Ovarian Cancer
0:08:26
Regorafenib in Advanced Colorectal Cancer: Dosing Strategies
0:05:47
Global drug pricing: How cost-effective is bevacizumab?
0:04:25
Adjuvant Chemotherapy + Bevacizumab for Ovarian Cancer
Комментарии